pharma · Glioblastoma · Unresectable or metastatic soft tissue sarcoma
Philogen
Philogen S.p.A.
Philogen clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Loc. Bellaria, 35, Sovicille, SIENA 53018, IT
- Founded
- 1996
- Employees
- 180
- Programs
- 18
- Drugs
- 29
- Patents
- 0
Philogen projects
7 ClinicalTrials.gov programs sponsored by Philogen.
Philogen has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
PH-ACP3GA-01/24
Philogen S.p.A.
Patients with prostate cancer with: -suspected metastasis who are candidates for initial definitive therapy -suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) -metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands
1 trial -
PH-ACP3GA-03/25
Philogen S.p.A.
Patients with prostate cancer with: - suspected metastasis who are candidates for initial definitive therapy - suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) - metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands
1 trial -
PH-CAIXGA-02/24
Philogen S.p.A.
Patients with suspected clear cell renal cell carcinoma (ccRCC)
1 trial -
PH-F8IL10INTRA-03/24
Philogen S.p.A.
Patients with Rheumatoid Arthritis (RA) who, despite treatment with stable doses (for at least 3 months) of disease-modifying antirheumatic drugs (DMARDs, conventional, biologic and/or targeted synthetic), present arthritis flare(s) suitable for intra-articular (IA) injection in a knee, shoulder, ankle, wrist or elbow.
1 trial -
PH-FAPLU-02-23
Philogen S.p.A.
Patients with advanced/metastatic FAP-positive tumors
1 trial -
PH-L19IL2CORK-01/25
Philogen S.p.A.
Advanced solid tumors, specifically: • metastatic clear cell renal carcinoma • proficient mismatch repair / microsatellite stable (pMMR/MSS), BRAF-V600E-mutant negative colorectal carcinoma • locally advanced or metastatic pancreatic adenocarcinoma
1 trial -
Safety and Early Signs of Efficacy of IL12-L19L19
Philogen S.p.A.
Advanced or metastatic carcinomas after previous immune checkpoint blockade therapy
1 trial
Frequently asked questions
How many clinical projects does Philogen have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.